Meet the Goldman Sachs execs tasked with building the firm's new Blackstone-esque private-investing unit, and pumping up the bank's flagging stock price

The execs to run it are Julian Salisbury, Andrew Wolff, and Sumit Rajpal, who will serve as heads, and Rich Friedman, who will chair the division.

June 18, 2019   |   View Online »

Meet the Goldman Sachs execs tasked with building the firm's new Blackstone-esque private-investing unit, and pumping up the bank's flagging stock price Dakin Campbell | The execs to run it are Julian Salisbury, Andrew Wolff, and Sumit Rajpal, who will serve as heads, and Rich Friedman, who will chair the division. Read More »

Citigroup launched a major restructuring of 2 of its top moneymaking units in sales and trading. We got the internal memo. Alex Morrell | Citi is merging its rates and currencies businesses, two of the top moneymakers in its $11.6 billion FICC division, it announced in an internal memo. Read More »

Employees of unicorns are cashing out before their start-up goes public. It shows how rocky this year's big IPOs have been. Bradley Saacks | The public debuts of Lyft and Uber have spooked some employees in Silicon Valley, who want to get cash before the market potentially devalues their shares, according to Forge. Read More »

High-speed trading firm GTS is making a push into the rapidly-changing bond market, and the CEO says 'there is so much we can do' Dan DeFrancesco | GTS is planning to build upon its recently acquired ETF business to begin making markets in US corporate bonds. Read More »

The stock market is entering its 2 most important weeks of the year. Here's what Wall Street experts recommend to navigate the chaos and make a killing. Akin Oyedele | The outcomes of the Fed's meeting on Wednesday and the G20 summit next week are of market-moving importance to investors. Read More »

An under-the-radar market signal just crossed a crucial threshold. Here's how you can profit from the surprising shift. Christopher Competiello | Evercore ISI breaks down the recent convergence of stock and bond yields, and how to profit from the implications. Read More »

3 biotechs that investors should buy next after Pfizer's $11 billion deal for cancer drugmaker Array BioPharma Clarrie Feinstein,Emma Court | Several other biotechs are also developing "targeted" cancer drugs that aim to better fight the disease. Read More »

A top credit salesman at Bank of America Merrill Lynch has left after nearly 15 years Alex Morrell | Brian Kirkwood was a managing director in investment-grade credit sales and joined the firm in 2005. Read More »

'The stakes have gotten higher': MediaMath is trying to block ad fraud before it happens and will offer vetting tools for free to advertisers Lauren Johnson | The tactic is becoming increasingly common among ad-tech companies, including MediaMath competitors The Trade Desk and AppNexus. Read More »

Pfizer just struck an $11 billion deal, and it marks an ambitious shift in the US drug giant's blockbuster cancer strategy Emma Court | Pfizer is buying the biotech Array BioPharma for $11 billion. Array makes 'targeted' cancer drugs designed to do a better job of fighting the disease. Read More »

Share This Email    Read Business Insider On The Go

Email sent to: nguyenvu1187.love5@blogger.com Manage your email preferences   |   Unsubscribe Terms of Service   |   Privacy Policy Business Insider. 150 Fifth Ave, New York, NY 10011